Oncology biotech Seattle Genetics (NASDAQ:SGEN) has had a bit of an interesting ride since I reviewed the company's prospects and valuation
back in December. The shares moved up about 40% through February of
this year on optimism for the company's deep portfolio of antibody drug
conjugate (or ADC) compounds, not to mention biotech enthusiasm in
general, before getting caught up in the great biotech washout and fears
tied to the safety of lead drug Adcetris and changes to clinical
trials. Add in some concerns about competition from immuno-oncology
drugs and there's a lot to digest. When it is all said and done, not all
that much has changed on a "net basis" in my view - Seattle Genetics
doesn't look as compelling on a value basis, but there's significant
upside if clinical trial read-outs de-risk the pipeline.
Please continue here:
Risk And Reward Seem Pretty Balanced At Seattle Genetics
No comments:
Post a Comment